Pharmaceutical Technology5h
AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership
AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 ...
Pharmaceutical Technology5h
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
Pharmaceutical Technology6h
Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases
The European Commission (EC) has granted marketing authorisation for Sandoz ‘s Afqlir, a biosimilar to the reference medicine ...
Pharmaceutical Technology9h
AbbVie’s Elahere wins European approval for certain ovarian cancers
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Pharmaceutical Technology9h
FDA approves Syndax’s Revuforj to treat leukaemia
The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.
Pharmaceutical Technology10h
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically ...
Pharmaceutical Technology11h
AHA 2024: Lerodalciep provides promising results in open-label extension trial, LIBERATE-OLE
At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving ...
Pharmaceutical Technology12h
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...
Pharmaceutical Technology2d
Merative MarketScan
The FDA has released final draft recommendations for using real-world data and evidence in drug development.
Pharmaceutical Technology3d
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...
Pharmaceutical Technology3d
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Pharmaceutical Technology3d
FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...